Initial Diagnostic Workup of Acute Leukemia: Guideline From the College of American Pathologists and the American Society of Hematology.

CONTEXT - A complete diagnosis of acute leukemia requires knowledge of clinical information combined with morphologic evaluation, immunophenotyping and karyotype analysis, and often, molecular genetic testing. Although many aspects of the workup for acute leukemia are well accepted, few guidelines have addressed the different aspects of the diagnostic evaluation of samples from patients suspected to have acute leukemia. OBJECTIVE - To develop a guideline for treating physicians and pathologists involved in the diagnostic and prognostic evaluation of new acute leukemia samples, including acute lymphoblastic leukemia, acute myeloid leukemia, and acute leukemias of ambiguous lineage. DESIGN - The College of American Pathologists and the American Society of Hematology convened a panel of experts in hematology and hematopathology to develop recommendations. A systematic evidence review was conducted to address 6 key questions. Recommendations were derived from strength of evidence, feedback received during the public comment period, and expert panel consensus. RESULTS - Twenty-seven guideline statements were established, which ranged from recommendations on what clinical and laboratory information should be available as part of the diagnostic and prognostic evaluation of acute leukemia samples to what types of testing should be performed routinely, with recommendations on where such testing should be performed and how the results should be reported. CONCLUSIONS - The guideline provides a framework for the multiple steps, including laboratory testing, in the evaluation of acute leukemia samples. Some aspects of the guideline, especially molecular genetic testing in acute leukemia, are rapidly changing with new supportive literature, which will require on-going updates for the guideline to remain relevant.

[1]  K. Manola Cytogenetic abnormalities in acute leukaemia of ambiguous lineage: an overview , 2013, British journal of haematology.

[2]  H. Kantarjian,et al.  Rapid and reliable confirmation of acute promyelocytic leukemia by immunofluorescence staining with an antipromyelocytic leukemia antibody , 2010, Cancer.

[3]  M. Loh,et al.  Intrachromosomal amplification of chromosome 21 is associated with inferior outcomes in children with acute lymphoblastic leukemia treated in contemporary standard-risk children's oncology group studies: a report from the children's oncology group. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. Slovak,et al.  Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study. , 2008, Blood.

[5]  Paola Fazi,et al.  Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1). , 2010, Blood.

[6]  J. Hess,et al.  Acute myeloid leukemia diagnosis in the 21st century. , 2010, Archives of pathology & laboratory medicine.

[7]  Takashi Akasaka,et al.  Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol. , 2010, Blood.

[8]  A. Hagenbeek,et al.  A novel CBFA2 single-nucleotide mutation in familial platelet disorder with propensity to develop myeloid malignancies. , 2001, Blood.

[9]  Dario Campana,et al.  Detection of minimal residual disease in pediatric acute lymphoblastic leukemia , 2013, Cytometry. Part B, Clinical cytometry.

[10]  I. Bernstein,et al.  Molecular alterations of the IDH1 gene in AML: a Children’s Oncology Group and Southwest Oncology Group study , 2010, Leukemia.

[11]  J. D. Vos,et al.  PAX5 mutations occur frequently in adult B-cell progenitor acute lymphoblastic leukemia and PAX5 haploinsufficiency is associated with BCR-ABL1 and TCF3-PBX1 fusion genes: a GRAALL study , 2009, Leukemia.

[12]  M. Tallman,et al.  How I treat acute promyelocytic leukemia. , 2009, Blood.

[13]  R. Hills,et al.  TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis , 2009, Leukemia.

[14]  S. Richards,et al.  Minimal residual disease is a significant predictor of treatment failure in non T‐lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993 , 2010, British journal of haematology.

[15]  R. Hills,et al.  Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial. , 2007, Blood.

[16]  E. Hendriks,et al.  Considered judgement in evidence-based guideline development. , 2006, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[17]  B. Falini,et al.  Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype. , 2005, Blood.

[18]  Manuela Zucknick,et al.  IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  H Austin,et al.  Benzene and leukemia. A review of the literature and a risk assessment. , 1988, American journal of epidemiology.

[20]  M. Litzow,et al.  Conventional karyotyping and fluorescence in situ hybridization: an effective utilization strategy in diagnostic adult acute myeloid leukemia. , 2015, American journal of clinical pathology.

[21]  Harris,et al.  Extra‐medullary myeloid tumour (granulocytic sarcoma) is often misdiagnosed: a study of 26 cases , 1999, Histopathology.

[22]  Marcos González,et al.  The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia , 2008, Haematologica.

[23]  E. Estey,et al.  Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center. , 2006, Blood.

[24]  R. Siebert,et al.  DNA Methylation Profiles and Their Relationship with Cytogenetic Status in Adult Acute Myeloid Leukemia , 2010, PloS one.

[25]  D. Bourderont,et al.  Peripheral blood and BM CD34+ CD38- cells show better resistance to cryopreservation than CD34+ CD38+ cells in autologous stem cell transplantation. , 2004, Cytotherapy.

[26]  Hong Chang,et al.  Extramedullary infiltrates of AML are associated with CD56 expression, 11q23 abnormalities and inferior clinical outcome. , 2004, Leukemia research.

[27]  B. Ko,et al.  Risk factors and clinical outcomes of acute myeloid leukaemia with central nervous system involvement in adults , 2015, BMC Cancer.

[28]  W. Hiddemann,et al.  Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. , 2005, Blood.

[29]  K. Honma,et al.  GATA-2 anomaly and clinical phenotype of a sporadic case of lymphedema, dendritic cell, monocyte, B- and NK-cell (DCML) deficiency, and myelodysplasia , 2012, European Journal of Pediatrics.

[30]  H. Gralnick,et al.  Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML‐MO) , 1991, British journal of haematology.

[31]  M. Sanz,et al.  Central nervous system involvement at first relapse in patients with acute myeloid leukemia , 2011, Haematologica.

[32]  N R Schneider,et al.  Precursor B-cell lymphoblastic lymphoma. A study of nine cases lacking blood and bone marrow involvement and review of the literature. , 2001, American journal of clinical pathology.

[33]  R. Srinivasan,et al.  Precursor T‐lymphoblastic lymphoma: Speedy diagnosis in FNA and effusion cytology by morphology, immunochemistry, and flow cytometry , 2015, Cancer cytopathology.

[34]  M. McElrath,et al.  Enumeration of major peripheral blood leukocyte populations for multicenter clinical trials using a whole blood phenotyping assay. , 2012, Journal of visualized experiments : JoVE.

[35]  T. Vulliamy,et al.  Defining the pathogenic role of telomerase mutations in myelodysplastic syndrome and acute myeloid leukemia , 2009, Human mutation.

[36]  Heather L. Mulder,et al.  Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. , 2014, The New England journal of medicine.

[37]  E. Freireich,et al.  Natural history of central nervous system acute leukemia in adults , 1981, Cancer.

[38]  Chi Tang,et al.  Acute leukemia presenting with blasts first found in the cerebrospinal fluid but not in the peripheral blood , 2010, Journal of Clinical Neuroscience.

[39]  C C Bailey,et al.  Gender and treatment outcome in childhood lymphoblastic leukaemia: report from the MRC UKALL trials * , 1995, British journal of haematology.

[40]  P. Hokland,et al.  Sensitivity of minimal residual disease in acute myeloid leukaemia in first remission – methodologies in relation to their clinical situation , 2012, British journal of haematology.

[41]  J. Buckley,et al.  Extramedullary Leukemia in Children With Newly Diagnosed Acute Myeloid Leukemia: A Report From the Children's Cancer Group , 2003, Journal of pediatric hematology/oncology.

[42]  P. Rohrlich,et al.  Cutaneous involvement in children with acute lymphoblastic leukemia or lymphoblastic lymphoma. The Children's Leukemia Cooperative Group of the European Organization of Research and Treatment of Cancer (EORTC). , 1997, Pediatrics.

[43]  W. Kamps,et al.  High VEGFC expression is associated with unique gene expression profiles and predicts adverse prognosis in pediatric and adult acute myeloid leukemia. , 2010, Blood.

[44]  C. Eckert,et al.  Immunoglobulin and T-cell receptor gene rearrangements as PCR-based targets are stable markers for monitoring minimal residual disease in acute lymphoblastic leukemia after stem cell transplantation , 2009, Leukemia.

[45]  Gerhard Ehninger,et al.  Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). , 2006, Blood.

[46]  M. Loh,et al.  Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). , 2007, Blood.

[47]  S. Fröhling,et al.  Risk-adapted postremission therapy in acute myeloid leukemia: results of the german multicenter AML HD93 treatment trial , 2003, Leukemia.

[48]  M. Eguchi,et al.  Clinical features and outcome of MLL gene rearranged acute lymphoblastic leukemia in infants with additional chromosomal abnormalities other than 11q23 translocation. , 2008, Leukemia research.

[49]  C. Bloomfield,et al.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.

[50]  R. Porcher,et al.  Prognostic factors for leukemic induction failure in children with acute lymphoblastic leukemia and outcome after salvage therapy: the FRALLE 93 study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  J. Rowley,et al.  Chromosomal translocations in secondary acute myeloid leukemia. , 1996, The New England journal of medicine.

[52]  Y. Liang,et al.  AML1-ETO9a is correlated with C-KIT overexpression/mutations and indicates poor disease outcome in t(8;21) acute myeloid leukemia-M2 , 2009, Leukemia.

[53]  M. Caligiuri,et al.  Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  Liang Huang,et al.  Potential application of IDH1 and IDH2 mutations as prognostic indicators in non-promyelocytic acute myeloid leukemia: a meta-analysis , 2012, Leukemia & lymphoma.

[55]  S. Raimondi,et al.  Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. , 2009, Blood.

[56]  J. Bennett,et al.  Diagnostic criteria to distinguish hypocellular acute myeloid leukemia from hypocellular myelodysplastic syndromes and aplastic anemia: recommendations for a standardized approach , 2009, Haematologica.

[57]  M. Markey,et al.  Genomic DNA extraction methods using formalin-fixed paraffin-embedded tissue. , 2015, Analytical biochemistry.

[58]  J. Lancet,et al.  Diagnostic immunophenotype of acute promyelocytic leukemia before and early during therapy with all-trans retinoic acid. , 2014, American journal of clinical pathology.

[59]  A. Kohlmann,et al.  AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features. , 2009, Blood.

[60]  S. Jewell,et al.  Copyright © American Society for Investigative Pathology Review Effect of Fixatives and Tissue Processing on the Content and Integrity of Nucleic Acids , 2022 .

[61]  Mats G Gustafsson,et al.  DNA methylation for subtype classification and prediction of treatment outcome in patients with childhood acute lymphoblastic leukemia. , 2010, Blood.

[62]  Keith Wheatley,et al.  Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials , 2009, British journal of haematology.

[63]  T. Carey,et al.  Tissue‐preserving approach to extracting DNA from paraffin‐embedded specimens using tissue microarray technology , 2007, Head & neck.

[64]  M. Caligiuri,et al.  Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. , 2001, Cancer research.

[65]  H. Avet-Loiseau Fish analysis at diagnosis in acute lymphoblastic leukemia. , 1999, Leukemia & lymphoma.

[66]  M. Montes,et al.  Cryopreservation modulates the detection of regulatory T cell markers , 2012, Cytometry. Part B, Clinical cytometry.

[67]  K. Döhner,et al.  Gene-specific and global methylation patterns predict outcome in patients with acute myeloid leukemia , 2010, Leukemia.

[68]  R. Greil,et al.  Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG). , 2013, Blood.

[69]  K. Döhner,et al.  Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome. , 2009, Blood.

[70]  C. J. Kim,et al.  Granulocytic sarcoma in MLL-positive infant acute myelogenous leukemia: fluorescence in situ hybridization study of childhood acute myelogenous leukemia for detecting MLL rearrangement. , 2001, The American journal of pathology.

[71]  Annelyse Bruwier,et al.  Hematological disorders and leukemia in children with Down syndrome , 2012, European Journal of Pediatrics.

[72]  C. Bloomfield,et al.  Central review of cytogenetics is necessary for cooperative group correlative and clinical studies of adult acute leukemia: the Cancer and Leukemia Group B experience. , 2008, International journal of oncology.

[73]  M. Bui,et al.  A practical approach to diagnose soft tissue myeloid sarcoma preceding or coinciding with acute myeloid leukemia. , 2014, Annals of diagnostic pathology.

[74]  L. Bernal-Mizrachi,et al.  Sensitivity and specificity of cerebrospinal fluid flow cytometry for the diagnosis of leukemic meningitis in acute lymphoblastic leukemia/lymphoma , 2014, Leukemia & lymphoma.

[75]  M. Caligiuri,et al.  Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia. , 2011, Blood.

[76]  R. Hanada,et al.  Extramedullary infiltration at diagnosis and prognosis in children with acute myelogenous leukemia , 2007, Pediatric blood & cancer.

[77]  E. Archimbaud,et al.  Expression of immunological markers on leukemic cells before and after cryopreservation and thawing. , 1988, Cryobiology.

[78]  L. Medeiros,et al.  Extramedullary Manifestations of Myeloid Neoplasms. , 2015, American journal of clinical pathology.

[79]  A. C. Chinault,et al.  Syndromic thrombocytopenia and predisposition to acute myelogenous leukemia caused by constitutional microdeletions on chromosome 21q. , 2008, Blood.

[80]  Adam J Mead,et al.  The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. , 2008, Blood.

[81]  K. Döhner,et al.  Prognostic factors in adult patients up to 60 years old with acute myeloid leukemia and translocations of chromosome band 11q23: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[82]  R. Cheney,et al.  Genomic profiling of myeloid sarcoma by array comparative genomic hybridization , 2005, Genes, chromosomes & cancer.

[83]  J. Radich,et al.  Structural and numerical variation of FLT3/ITD in pediatric AML. , 2008, Blood.

[84]  E. Hoster,et al.  Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[85]  David Wu,et al.  Detection of Minimal Residual Disease in B Lymphoblastic Leukemia by High-Throughput Sequencing of IGH , 2014, Clinical Cancer Research.

[86]  T. Pabst,et al.  Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemia. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[87]  D. Arber,et al.  Challenges in Consolidated Reporting of Hematopoietic Neoplasms. , 2013, Surgical pathology clinics.

[88]  A. Órfão,et al.  Mixed phenotype acute leukemia (MPAL): clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification Authors: , 2011 .

[89]  D. Sayed,et al.  Immunophenotyping and immunoglobulin heavy chain gene rearrangement analysis in cerebrospinal fluid of pediatric patients with acute lymphoblastic leukemia. , 2009, Leukemia research.

[90]  J. Baust,et al.  Biobanking: The Future of Cell Preservation Strategies. , 2015, Advances in experimental medicine and biology.

[91]  Y. Hayashi,et al.  KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study Group. , 2006, Blood.

[92]  M. Caligiuri,et al.  MicroRNA expression in cytogenetically normal acute myeloid leukemia. , 2008, The New England journal of medicine.

[93]  L. Peterson,et al.  Protocol for the examination of specimens from patients with hematopoietic neoplasms of the bone marrow: a basis for checklists. , 2002, Archives of pathology & laboratory medicine.

[94]  Daniel G Tenen,et al.  Dysregulation of the C/EBPalpha differentiation pathway in human cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[95]  W. Lam,et al.  DNA Extraction from Paraffin Embedded Material for Genetic and Epigenetic Analyses , 2011, Journal of visualized experiments : JoVE.

[96]  R. Larson Cytogenetics, not just previous therapy, determines the course of therapy-related myeloid neoplasms. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[97]  R. Hills,et al.  Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. , 2010, Blood.

[98]  K. Döhner,et al.  Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[99]  B. Johansson,et al.  Outcome of ETV6/RUNX1‐positive childhood acute lymphoblastic leukaemia in the NOPHO‐ALL‐1992 protocol: frequent late relapses but good overall survival , 2008, British journal of haematology.

[100]  Elie A Akl,et al.  GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. , 2013, Journal of clinical epidemiology.

[101]  M. Caligiuri,et al.  IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[102]  C. Pui,et al.  Prospective analysis of TEL gene rearrangements in childhood acute lymphoblastic leukemia: a Children's Oncology Group study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[103]  G. Ehninger,et al.  The prognostic impact of 17p (p53) deletion in 2272 adults with acute myeloid leukemia , 2009, Leukemia.

[104]  N. Heerema,et al.  Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group Study AALL0031 , 2014, Leukemia.

[105]  Benjamin J. Raphael,et al.  Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.

[106]  K. Wagner,et al.  Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[107]  E. Weir,et al.  A limited antibody panel can distinguish B-precursor acute lymphoblastic leukemia from normal B precursors with four color flow cytometry: implications for residual disease detection , 1999, Leukemia.

[108]  S. Meshinchi,et al.  Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia , 2005, Leukemia.

[109]  M. Tallman,et al.  Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. , 2005, Blood.

[110]  S. Paydaş,et al.  Granulocytic sarcoma: 32 cases and review of the literature , 2006, Leukemia & lymphoma.

[111]  F. Speleman,et al.  NOTCH1 and FBXW7 mutations have a favorable impact on early response to treatment, but not on outcome, in children with T-cell acute lymphoblastic leukemia (T-ALL) treated on EORTC trials 58881 and 58951 , 2010, Leukemia.

[112]  D. Subirá,et al.  Flow cytometry and the study of central nervous disease in patients with acute leukaemia , 2001, British journal of haematology.

[113]  R. Hills,et al.  The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia , 2013, Leukemia.

[114]  J. Downing,et al.  Increased risk for CNS relapse in pre-B cell leukemia with the t(1;19)/TCF3-PBX1 , 2009, Leukemia.

[115]  K. Wheatley,et al.  Relationships between age at diagnosis, clinical features, and outcome of therapy in children treated in the Medical Research Council AML 10 and 12 trials for acute myeloid leukemia. , 2001, Blood.

[116]  H. Gralnick,et al.  Proposals for the Classification of the Acute Leukaemias French‐American‐British (FAB) Co‐operative Group , 1976, British journal of haematology.

[117]  L. Medeiros,et al.  Pure erythroid leukemia: a reassessment of the entity using the 2008 World Health Organization classification , 2011, Modern Pathology.

[118]  T. Lister,et al.  Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[119]  Z. Estrov,et al.  Incidence of and risk factors for involvement of the central nervous system in acute myeloid leukemia , 2015, Leukemia & lymphoma.

[120]  John M. Maris,et al.  Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia , 1999, Nature Genetics.

[121]  R. Larson,et al.  Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[122]  J. Merker,et al.  Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations , 2015, Modern Pathology.

[123]  J. Byrd,et al.  Extramedullary myeloid cell tumors in acute nonlymphocytic leukemia: a clinical review. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[124]  C Haferlach,et al.  The role of different genetic subtypes of CEBPA mutated AML , 2014, Leukemia.

[125]  F. Behm,et al.  Low leukocyte counts with blast cells in cerebrospinal fluid of children with newly diagnosed acute lymphoblastic leukemia. , 1993, The New England journal of medicine.

[126]  M. Caligiuri,et al.  Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[127]  T. Walsh,et al.  Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy‐related leukemia , 2016, Cancer.

[128]  M. Relling,et al.  Traumatic lumbar puncture at diagnosis adversely affects outcome in childhood acute lymphoblastic leukemia. , 2000, Blood.

[129]  Bruce Greig,et al.  2006 Bethesda International Consensus recommendations on the immunophenotypic analysis of hematolymphoid neoplasia by flow cytometry: Optimal reagents and reporting for the flow cytometric diagnosis of hematopoietic neoplasia , 2007, Cytometry. Part B, Clinical cytometry.

[130]  Brenda Y. Hernandez,et al.  Robustness of Next Generation Sequencing on Older Formalin-Fixed Paraffin-Embedded Tissue , 2015, PloS one.

[131]  A. Ciocco,et al.  Radiation-related leukemia in Hiroshima and Nagasaki 1946--1964. II. , 1967, Annals of internal medicine.

[132]  B. Wilkins Pitfalls in bone marrow pathology: avoiding errors in bone marrow trephine biopsy diagnosis , 2011, Journal of Clinical Pathology.

[133]  Christian Langer,et al.  Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[134]  Y. Nojima,et al.  Philadelphia chromosome‐positive mixed phenotype acute leukemia in the imatinib era , 2014, European journal of haematology.

[135]  C. Bloomfield,et al.  Cytogenetics in acute leukemia. , 2004, Blood reviews.

[136]  G. Dewald,et al.  Efficacy of fluorescence in situ hybridization for detecting PML/RARA gene fusion in treated and untreated acute promyelocytic leukemia. , 1994, Mayo Clinic proceedings.

[137]  A. Hagemeijer,et al.  Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[138]  J. Rowley The Role of Cytogenetics in Hematology , 1976 .

[139]  H. Popper,et al.  Evaluation of formalin-free tissue fixation for RNA and microRNA studies. , 2011, Experimental and molecular pathology.

[140]  D. Catovsky,et al.  Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group. , 1985, Annals of internal medicine.

[141]  J. Esteve,et al.  Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens. , 2011, Blood.

[142]  M. Jaakkola,et al.  Exposure to benzene at work and the risk of leukemia: a systematic review and meta-analysis , 2010, Environmental health : a global access science source.

[143]  N. Schmitz,et al.  Risk stratification using a new prognostic score for patients with secondary acute myeloid leukemia: results of the prospective AML96 trial , 2011, Leukemia.

[144]  T. Pabst,et al.  Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis , 2009, British Journal of Cancer.

[145]  B. Johansson,et al.  Incidence and prognostic significance of karyotypic subgroups in older patients with acute myeloid leukemia: the Swedish population-based experience , 2014, Blood Cancer Journal.

[146]  S. Çağırgan,et al.  The loss of CD34+ cells in peripheral hematopoietic stem cell products cryopreserved by non-controlled rate freezing and stored at -80 °C after overnight storage. , 2014, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[147]  C. Pui,et al.  Prognostic factors and outcome of recurrence in childhood acute myeloid leukemia , 2007, Cancer.

[148]  T. Owaidah,et al.  Validation of a modified cryopreservation method for leukemic blasts for flow cytometry assessment. , 2008, Hematology/oncology and stem cell therapy.

[149]  A. Ciocco,et al.  Radiation-related leukemia in Hiroshima and Nagasaki, 1946-1964. I. Distribution, incidence and appearance time. , 1966, The New England journal of medicine.

[150]  K. Mrózek,et al.  Cytogenetics and molecular genetics of acute lymphoblastic leukemia. , 2009, Hematology/oncology clinics of North America.

[151]  B. Johansson,et al.  The frequency and prognostic impact of dic(9;20)(p13.2;q11.2) in childhood B-cell precursor acute lymphoblastic leukemia: results from the NOPHO ALL-2000 trial , 2011, Leukemia.

[152]  V. V. D. van der Velden,et al.  Defining consensus leukemia-associated immunophenotypes for detection of minimal residual disease in acute myeloid leukemia in a multicenter setting , 2013, Blood Cancer Journal.

[153]  Holly M Knoderer,et al.  Central nervous system involvement at the time of presentation in acute promyelocytic leukemia , 2010, Pediatric blood & cancer.

[154]  Tariq Enver,et al.  Haploinsufficiency of GATA-2 perturbs adult hematopoietic stem-cell homeostasis. , 2005, Blood.

[155]  W. van Putten,et al.  Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. , 2010, Blood.

[156]  C. Bloomfield,et al.  New recurrent balanced translocations in acute myeloid leukemia and myelodysplastic syndromes: Cancer and leukemia group B 8461 , 2013, Genes, chromosomes & cancer.

[157]  T. Naoe,et al.  Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome , 2007, European journal of haematology.

[158]  A. Sun,et al.  Clinical Characteristics, Biological Profile, and Outcome of Biphenotypic Acute Leukemia: A Case Series , 2011, Acta Haematologica.

[159]  W. Hiddemann,et al.  1 KIT-D 816 mutations in AML 1-ETO positive AML are associated with impaired event-free and overall survival , 2005 .

[160]  M. Andersen,et al.  Therapy‐related acute lymphoblastic leukaemia with MLL rearrangements following DNA topoisomerase II inhibitors, an increasing problem: report on two new cases and review of the literature since 1992 , 2001, British journal of haematology.

[161]  L. Godley Inherited predisposition to acute myeloid leukemia. , 2014, Seminars in hematology.

[162]  C. Craddock,et al.  Guidelines on the management of acute myeloid leukaemia in adults , 2006, British journal of haematology.

[163]  J. Neglia,et al.  Myelodysplastic syndrome after autologous bone marrow transplantation: an additional late complication of curative cancer therapy. , 1994, Blood.

[164]  W. Hiddemann,et al.  A new prognostic score for patients with acute myeloid leukemia based on cytogenetics and early blast clearance in trials of the German AML Cooperative Group. , 2004, Haematologica.

[165]  Alan M. Miller,et al.  Classifying cytogenetics in patients with acute myelogenous leukemia in complete remission undergoing allogeneic transplantation: a Center for International Blood and Marrow Transplant Research study. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[166]  E. Clappier,et al.  Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia , 2008, The Journal of experimental medicine.

[167]  R. Hills,et al.  Impact of FLT3(ITD) mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia. , 2014, Blood.

[168]  S. Devlin,et al.  Secondary acute lymphoblastic leukaemia is constitutional and probably not related to prior therapy , 2015, British journal of haematology.

[169]  C. Bloomfield,et al.  Central nervous system involvement in acute nonlymphocytic leukemia. A prospective study of adults in remission. , 1987, The American journal of medicine.

[170]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.

[171]  R Mastrangelo,et al.  Report and recommendations of the Rome workshop concerning poor-prognosis acute lymphoblastic leukemia in children: biologic bases for staging, stratification, and treatment. , 1986, Medical and pediatric oncology.

[172]  S. Pileri,et al.  Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients , 2007, Leukemia.

[173]  Maria Grazia Valsecchi,et al.  Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[174]  G. Lutz,et al.  Nanopolymers improve delivery of exon skipping oligonucleotides and concomitant dystrophin expression in skeletal muscle of mdx mice , 2008, BMC biotechnology.

[175]  R. Riley,et al.  Bone marrow aspirate and biopsy: a pathologist's perspective. II. interpretation of the bone marrow aspirate and biopsy , 2009, Journal of clinical laboratory analysis.

[176]  Y. Mun,et al.  Clinical utility of FISH analysis in addition to G-banded karyotype in hematologic malignancies and proposal of a practical approach , 2010, The Korean journal of hematology.

[177]  W. Hiddemann,et al.  ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: a comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[178]  C. Pui,et al.  Clinical significance of central nervous system involvement at diagnosis of pediatric acute myeloid leukemia: a single institution's experience , 2003, Leukemia.

[179]  K. P. Kim,et al.  Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours: a retrospective cohort study , 2012, The Lancet.

[180]  A. LaCasce,et al.  Improving the quality of bone marrow assessment , 2013, Cancer.

[181]  D. Johnston,et al.  Superior outcome of pediatric acute myeloid leukemia patients with orbital and CNS myeloid sarcoma: A report from the Children's Oncology Group , 2012, Pediatric blood & cancer.

[182]  M. Tallman,et al.  IGH@ translocations, CRLF2 deregulation, and microdeletions in adolescents and adults with acute lymphoblastic leukemia. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[183]  Cheng Cheng,et al.  Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. , 2009, The Lancet. Oncology.

[184]  N. Rosenthal,et al.  Transient increase in blasts mimicking acute leukemia and progressing myelodysplasia in patients receiving growth factor. , 1998, American journal of clinical pathology.

[185]  K. Döhner,et al.  High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[186]  D. Johnston,et al.  The presence of central nervous system disease at diagnosis in pediatric acute myeloid leukemia does not affect survival: A Children's Oncology Group study , 2010, Pediatric blood & cancer.

[187]  D. Neuberg,et al.  A surrogate marker profile for PML/RARα expressing acute promyelocytic leukemia and the association of immunophenotypic markers with morphologic and molecular subtypes , 2004, Cytometry. Part B, Clinical cytometry.

[188]  A Orfao,et al.  EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes , 2012, Leukemia.

[189]  K. Döhner,et al.  The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. , 2011, Blood.

[190]  J. Ritter,et al.  Does cranial irradiation reduce the risk for bone marrow relapse in acute myelogenous leukemia? Unexpected results of the Childhood Acute Myelogenous Leukemia Study BFM-87. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[191]  Erdogan Taskesen,et al.  Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. , 2011, Blood.

[192]  The FLT3ITD mRNA level has a high prognostic impact in NPM1 mutated, but not in NPM1 unmutated, AML with a normal karyotype. , 2012, Blood.

[193]  J. Rowley Editorial: The role of cytogenetics in hematology. , 1976, Blood.

[194]  C. Bloomfield,et al.  Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[195]  C. Pui,et al.  Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[196]  W. Hiddemann,et al.  Stability of leukemia‐associated aberrant immunophenotypes in patients with acute myeloid leukemia between diagnosis and relapse: Comparison with cytomorphologic, cytogenetic, and molecular genetic findings , 2004, Cytometry. Part B, Clinical cytometry.

[197]  D. Johnston,et al.  Risk factors and therapy for isolated central nervous system relapse of pediatric acute myeloid leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[198]  S. Kamel‐Reid,et al.  Prognostic factors in normal karyotype acute myeloid leukemia in the absence of the FLT3-ITD mutation. , 2011, Leukemia research.

[199]  J. Cayuela,et al.  Long-term follow-up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: a GRAALL study. , 2013, Biology of Blood and Marrow Transplantation.

[200]  J. Bertino,et al.  Acute nonlymphocytic leukemia. A delayed complication of Hodgkin's disease therapy: Analysis of 109 cases , 1977, Cancer.

[201]  S. Feig,et al.  Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group. , 2008, Blood.

[202]  S. Pileri,et al.  Immunocytochemical diagnosis of acute promyelocytic leukemia (M3) with the monoclonal antibody PG-M3 (anti-PML). , 1997, Blood.

[203]  R. Pieters,et al.  Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML , 2009, Leukemia.

[204]  D. Campana,et al.  The immunophenotype of T‐lymphoblastic lymphoma in children and adolescents: a Children's Oncology Group report , 2012, British journal of haematology.

[205]  S. Jang,et al.  Morphologic detection of blast cells in the cerebrospinal fluid at diagnosis of adult acute lymphoblastic leukemia appears to be associated with adverse prognosis , 2014, International journal of laboratory hematology.

[206]  D. S. Lee,et al.  Fluorescence in situ hybridization (FISH) using snap frozen buffy coat. , 2007, Annals of clinical and laboratory science.

[207]  M. Caligiuri,et al.  TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[208]  J. Cayuela,et al.  Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). , 2002, Blood.

[209]  J. Bennett,et al.  Granulocytic sarcoma: A clinicopathologic study of 61 biopsied cases , 1981, Cancer.

[210]  S. Perkins,et al.  Optimized immunohistochemical panel to differentiate myeloid sarcoma from blastic plasmacytoid dendritic cell neoplasm , 2014, Modern Pathology.

[211]  Bas J. Wouters,et al.  Brief Report Results and Discussion , 2022 .

[212]  M. Caligiuri,et al.  FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. , 2008, Blood.

[213]  D. Dorfman,et al.  Precursor B-cell Lymphoblastic Lymphoma: A Predominantly Extranodal Tumor With Low Propensity for Leukemic Involvement , 2000, The American journal of surgical pathology.

[214]  F. Mancini,et al.  Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts , 2013, Haematologica.

[215]  J. Pedersen‐Bjergaard,et al.  Two different classes of therapy-related and de-novo acute myeloid leukemia? , 1991, Cancer genetics and cytogenetics.

[216]  James Allan,et al.  Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[217]  J. Starý,et al.  Monitoring of minimal residual disease in patients with core binding factor acute myeloid leukemia and the impact of C-KIT, FLT3, and JAK2 mutations on clinical outcome , 2009, Leukemia & lymphoma.

[218]  Anne-Mette K. Hein,et al.  Next-Generation Sequencing of RNA and DNA Isolated from Paired Fresh-Frozen and Formalin-Fixed Paraffin-Embedded Samples of Human Cancer and Normal Tissue , 2014, PloS one.

[219]  Paola Fazi,et al.  Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia , 2008, Haematologica.

[220]  M. Caligiuri,et al.  Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[221]  N. Nadal,et al.  Multiparametric analysis of normal and postchemotherapy bone marrow: Implication for the detection of leukemia‐associated immunophenotypes , 2008, Cytometry. Part B, Clinical cytometry.

[222]  V. Ivanov,et al.  Leukemia incidence in the Russian cohort of Chernobyl emergency workers , 2012, Radiation and environmental biophysics.

[223]  S. Holland,et al.  Acquired ASXL1 mutations are common in patients with inherited GATA2 mutations and correlate with myeloid transformation , 2014, Haematologica.

[224]  Pamela Casey Brief Reports , 1983, Violence and Victims.

[225]  E. Thiel,et al.  Wilms’ tumor gene 1 (WT1) expression in subtypes of acute lymphoblastic leukemia (ALL) of adults and impact on clinical outcome , 2009, Annals of Hematology.

[226]  J. Cigudosa,et al.  DNA profiling analysis of 100 consecutive de novo acute myeloid leukemia cases reveals patterns of genomic instability that affect all cytogenetic risk groups , 2007, Leukemia.

[227]  P. N. Rao,et al.  Detection of abnormal pretransplant clones in progenitor cells of patients who developed myelodysplasia after autologous transplantation. , 1999, Blood.

[228]  C. Harrison,et al.  Intrachromosomal amplification of chromosome 21 (iAMP21) may arise from a breakage–fusion–bridge cycle , 2007, Genes, chromosomes & cancer.

[229]  Cheng Cheng,et al.  Risk factors for traumatic and bloody lumbar puncture in children with acute lymphoblastic leukemia. , 2002, JAMA.

[230]  E. Berg,et al.  World Health Organization Classification of Tumours , 2002 .

[231]  Stuart H. Orkin,et al.  An early haematopoietic defect in mice lacking the transcription factor GATA-2 , 1994, Nature.

[232]  H. Dombret,et al.  NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study. , 2009, Blood.

[233]  H. Sonobe,et al.  Leukemia cutis. , 2007, Internal medicine.

[234]  C. Bloomfield,et al.  Prognostic implications of NOTCH1 and FBXW7 mutations in adult acute T-lymphoblastic leukemia , 2009, Haematologica.

[235]  N. Day,et al.  Second malignancies following testicular cancer, ovarian cancer and hodgkin's disease: An international collaborative study among cancer registries , 1987, International journal of cancer.

[236]  E. Thiel,et al.  High BAALC expression predicts chemoresistance in adult B-precursor acute lymphoblastic leukemia. , 2010, Blood.

[237]  T. Cox,et al.  Vitamin B-12 and folate deficiency presenting as leukaemia. , 1990, BMJ.

[238]  W. Evans,et al.  A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. , 2009, The Lancet. Oncology.

[239]  A. Veerman,et al.  IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL , 2010, Leukemia.

[240]  A. Ferrando,et al.  T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). , 2009, Blood.

[241]  Steven M Kornblau,et al.  Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. , 2004, Blood.

[242]  E. Thiel,et al.  CD56 expression in T-cell acute lymphoblastic leukemia is associated with non-thymic phenotype and resistance to induction therapy but no inferior survival after risk-adapted therapy , 2009, Haematologica.

[243]  Mario Cazzola,et al.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.

[244]  J. Esteve,et al.  Adverse impact of IDH1 and IDH2 mutations in primary AML: experience of the Spanish CETLAM group. , 2012, Leukemia research.

[245]  L. Bullinger,et al.  Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation. , 2014, Blood.

[246]  J. Downing,et al.  Long-term results of St. Jude Total Therapy studies 11, 12, 13A, 13B and 14 for childhood acute lymphoblastic leukemia , 2009, Leukemia.

[247]  D. Birnbaum,et al.  Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes , 2015, Oncotarget.

[248]  H. Lee,et al.  Comparison of laboratory characteristics between acute promyelocytic leukemia and other subtypes of acute myeloid leukemia with disseminated intravascular coagulation , 2013, Blood research.

[249]  T. Naoe,et al.  High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[250]  L. Saft,et al.  Detection of central nervous system involvement in childhood acute lymphoblastic leukemia by cytomorphology and flow cytometry of the cerebrospinal fluid , 2015, Pediatric blood & cancer.

[251]  A. Look,et al.  Central Nervous System Leukemia in Children with Acute Nonlymphoblastic Leukemia , 1985 .

[252]  S. Fröhling,et al.  Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. , 2006, Blood.

[253]  G. Escherich,et al.  Cooperative study group for childhood acute lymphoblastic leukaemia (COALL): long-term results of trials 82,85,89,92 and 97 , 2010, Leukemia.

[254]  A. Bachand,et al.  Epidemiological studies of formaldehyde exposure and risk of leukemia and nasopharyngeal cancer: A meta-analysis , 2010, Critical reviews in toxicology.

[255]  P. Freemont,et al.  Characterization of cryptic rearrangements and variant translocations in acute promyelocytic leukemia. , 1997, Blood.

[256]  F. Lanza,et al.  Assessment of distribution of CD34 epitope classes in fresh and cryopreserved peripheral blood progenitor cells and acute myeloid leukemic blasts. , 1999, Haematologica.

[257]  S. Pileri,et al.  Cytoplasmic mutated nucleophosmin (NPM) defines the molecular status of a significant fraction of myeloid sarcomas , 2007, Leukemia.

[258]  Sonali M. Smith,et al.  Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. , 2003, Blood.

[259]  D. Karcher,et al.  Polymerase chain reaction detection of immunoglobulin gene rearrangement and bcl-2 translocation in archival glass slides of cytologic material. , 1995, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[260]  Marcos González,et al.  BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML) , 2010, Annals of Hematology.

[261]  Patricia A Stewart,et al.  Mortality from lymphohematopoietic malignancies and brain cancer among embalmers exposed to formaldehyde. , 2009, Journal of the National Cancer Institute.

[262]  W. Kamps,et al.  Minimal requirements for the diagnosis, classification, and evaluation of the treatment of childhood acute lymphoblastic leukemia (ALL) in the "BFM Family" Cooperative Group. , 1992, Medical and pediatric oncology.

[263]  Jianxiang Wang,et al.  Clinical characteristics and outcomes of mixed phenotype acute leukemia with Philadelphia chromosome positive and/or bcr-abl positive in adult , 2011, International journal of hematology.

[264]  B. Johansson,et al.  Clinical and cytogenetic features of a population‐based consecutive series of 285 pediatric T‐cell acute lymphoblastic leukemias: Rare T‐cell receptor gene rearrangements are associated with poor outcome , 2009, Genes, chromosomes & cancer.

[265]  E. Estey,et al.  Significance of FAB subclassification of "acute myeloid leukemia, NOS" in the 2008 WHO classification: analysis of 5848 newly diagnosed patients. , 2013, Blood.

[266]  K. Döhner,et al.  Prognostic DNA methylation patterns in cytogenetically normal acute myeloid leukemia are predefined by stem cell chromatin marks. , 2011, Blood.

[267]  U. Johansson,et al.  Guidelines on the use of multicolour flow cytometry in the diagnosis of haematological neoplasms , 2014, British journal of haematology.

[268]  S. Fröhling,et al.  TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. , 2012, Blood.

[269]  O. Abdel-Wahab,et al.  Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia. , 2013, Blood.

[270]  F. Appelbaum,et al.  Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: A southwest oncology group study (SWOG‐9500) , 2007, American journal of hematology.

[271]  Stefan Fröhling,et al.  Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. , 2005, Blood.

[272]  M. Gönen,et al.  CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900. , 2012, Blood.

[273]  R. Arceci,et al.  Minimally differentiated acute myeloid leukemia (FAB AML-M0) is associated with an adverse outcome in children: a report from the Children's Oncology Group, studies CCG-2891 and CCG-2961. , 2007, Blood.

[274]  Elisa Nemes,et al.  Differential leukocyte counting and immunophenotyping in cryopreserved ex vivo whole blood , 2015, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[275]  D. Bluteau,et al.  Thrombocytopenia-associated mutations in the ANKRD26 regulatory region induce MAPK hyperactivation. , 2014, The Journal of clinical investigation.

[276]  M. Valsecchi,et al.  Long-term results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster based chemotherapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[277]  C. Aitelli,et al.  Pernicious Anemia: Presentations Mimicking Acute Leukemia , 2004, Southern medical journal.

[278]  C. Bloomfield,et al.  High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study. , 2008, Blood.

[279]  H. Drexler,et al.  Clinical, immunophenotypic, cytogenetic, and molecular genetic features in 117 adult patients with mixed-phenotype acute leukemia defined by WHO-2008 classification , 2012, Haematologica.

[280]  H. Feilotter,et al.  An array-based analysis of microRNA expression comparing matched frozen and formalin-fixed paraffin-embedded human tissue samples. , 2008, The Journal of molecular diagnostics : JMD.

[281]  J. Rowe Prognostic factors in adult acute lymphoblastic leukaemia , 2010, British journal of haematology.

[282]  S. Richards,et al.  Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial. , 2010, The Lancet. Oncology.

[283]  R. Siebert,et al.  Epigenetic regulation of microRNAs in acute lymphoblastic leukemia. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[284]  A. Cherry,et al.  Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. , 2005, Blood.

[285]  O. Olopade,et al.  Proposal for the clinical detection and management of patients and their family members with familial myelodysplastic syndrome/acute leukemia predisposition syndromes , 2013, Leukemia & lymphoma.

[286]  E. Estey,et al.  Acute Myelogenous Leukemia , 2005 .

[287]  S. Perkins,et al.  Immunophenotypic profile of myeloid cells in granulocytic sarcoma by immunohistochemistry. Correlation with blast differentiation in bone marrow. , 2000, American journal of clinical pathology.

[288]  E. Ghia,et al.  Characterization of ABL1 expression in adult T-cell acute lymphoblastic leukemia by oligonucleotide array analysis. , 2007, Haematologica.

[289]  S. Lewis British Committee for Standards in Haematology , 1969 .

[290]  Christopher B. Miller,et al.  Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. , 2009, The New England journal of medicine.

[291]  G. Behre,et al.  Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. , 2001, Nature genetics.

[292]  K. Yamauchi,et al.  Comparison in treatments of nonleukemic granulocytic sarcoma , 2002, Cancer.

[293]  K. Wagner,et al.  Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[294]  C. Preudhomme,et al.  Another pedigree with familial acute myeloid leukemia and germline CEBPA mutation , 2009, Leukemia.

[295]  S. Hunger,et al.  Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children's Oncology Group. , 2010, Blood.

[296]  H. Dombret,et al.  Next-generation sequencing of FLT3 internal tandem duplications for minimal residual disease monitoring in acute myeloid leukemia , 2015, Oncotarget.

[297]  M. Slovak,et al.  Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study , 2000 .

[298]  W. Jędrzejczak,et al.  Status of minimal residual disease after induction predicts outcome in both standard and high‐risk Ph‐negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4‐2002 MRD Study , 2008, British journal of haematology.

[299]  R. Arceci,et al.  Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971. , 2011, Blood.

[300]  M. Bøgsted,et al.  Stable phenotype of B‐cell subsets following cryopreservation and thawing of normal human lymphocytes stored in a tissue biobank , 2014, Cytometry. Part B, Clinical cytometry.

[301]  N. Karandikar,et al.  Stability of leukemia-associated immunophenotypes in precursor B-lymphoblastic leukemia/lymphoma: a single institution experience. , 2007, American journal of clinical pathology.

[302]  S. Hunger,et al.  Long-term Results Of the Pediatric Oncology Group Studies For Childhood Acute Lymphoblastic Leukemia 1984-2001: A Report From The Children’s Oncology Group , 2009, Leukemia.

[303]  Rakesh Nagarajan,et al.  High throughput digital quantification of mRNA abundance in primary human acute myeloid leukemia samples. , 2009, The Journal of clinical investigation.

[304]  A. Porwit,et al.  ICSH guidelines for the standardization of bone marrow specimens and reports , 2008, International journal of laboratory hematology.

[305]  J. Buckley,et al.  Intensively timed induction therapy followed by autologous or allogeneic bone marrow transplantation for children with acute myeloid leukemia or myelodysplastic syndrome: a Childrens Cancer Group pilot study. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[306]  S. Richards,et al.  Risk-directed treatment intensification significantly reduces the risk of relapse among children and adolescents with acute lymphoblastic leukemia and intrachromosomal amplification of chromosome 21: a comparison of the MRC ALL97/99 and UKALL2003 trials. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[307]  J. Rowley,et al.  Lymphoblastic lymphoma in adults , 1981, Cancer.

[308]  S. Swerdlow WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues , 2017 .

[309]  A Orfao,et al.  Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). , 1995, Leukemia.

[310]  Z. Cayci,et al.  Intracranial CNS Manifestations of Myeloid Sarcoma in Patients with Acute Myeloid Leukemia: Review of the Literature and Three Case Reports from the Author’s Institution , 2015, Journal of clinical medicine.

[311]  F. Lo Coco,et al.  Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[312]  J. Cayuela,et al.  Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome – positive acute lymphoblastic leukemia : results of the GRAAPH-2003 study , 2006 .

[313]  Ulrich Mansmann,et al.  Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[314]  J. Krischer,et al.  High-dose cytarabine for intensification of early therapy of childhood acute myeloid leukemia: a Pediatric Oncology Group study. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[315]  C. Bloomfield,et al.  Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group. , 2010, Blood.

[316]  M. Caligiuri,et al.  BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. , 2010, Blood.

[317]  M. Kusumoto,et al.  Two Entities of Precursor T-Cell Lymphoblastic Leukemia/Lymphoma Based on Radiologic and Immunophenotypic Findings , 2004, International journal of hematology.

[318]  P. Rosenberg,et al.  Malignancies and survival patterns in the National Cancer Institute inherited bone marrow failure syndromes cohort study , 2010, British journal of haematology.

[319]  C. Bloomfield,et al.  Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience. , 1999, Blood.

[320]  Axel Benner,et al.  Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. , 2002, Blood.

[321]  A. Venditti,et al.  High sensitivity of flow cytometry improves detection of occult leptomeningeal disease in acute lymphoblastic leukemia and lymphoblastic lymphoma , 2014, Annals of Hematology.

[322]  M. Schrappe,et al.  Lineage Classification of Childhood Acute Lymphoblastic Leukemia according to the EGIL Recommendations: Results of the ALL-BFM 2000 Trial , 2013, Klinische Pädiatrie.

[323]  E. Chuang,et al.  A 3-microRNA scoring system for prognostication in de novo acute myeloid leukemia patients , 2014, Leukemia.

[324]  L. Bullinger,et al.  Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group. , 2009, Blood.

[325]  J. Downing,et al.  Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. , 2010, Blood.

[326]  M. Tallman,et al.  Cutaneous involvement with B-lineage acute lymphoblastic leukemia , 2012, Leukemia & lymphoma.

[327]  Yi Ning,et al.  Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. , 2006, Blood.

[328]  K. Zatloukal,et al.  Quality Control of RNA Preservation and Extraction from Paraffin-Embedded Tissue: Implications for RT-PCR and Microarray Analysis , 2013, PloS one.

[329]  G Flandrin,et al.  World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[330]  C. Bloomfield,et al.  Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). , 2002, Blood.

[331]  J. Gabert,et al.  Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects , 2003, Leukemia.

[332]  K. Zondervan,et al.  High-quality genomic DNA extraction from formalin-fixed and paraffin-embedded samples deparaffinized using mineral oil , 2009, Analytical biochemistry.

[333]  I. Bernstein,et al.  Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. , 2010, Blood.

[334]  R. Larson,et al.  Cytogenetic and genetic pathways in therapy-related acute myeloid leukemia. , 2010, Chemico-biological interactions.

[335]  H. Dombret,et al.  Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroup. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[336]  A. Cherry,et al.  Utility of interphase FISH to stratify patients into cytogenetic risk categories at diagnosis of AML in an Eastern Cooperative Oncology Group (ECOG) clinical trial (E1900). , 2007, Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis.

[337]  F. Prósper,et al.  Epigenetic regulation of Wnt-signaling pathway in acute lymphoblastic leukemia. , 2007, Blood.

[338]  G. Ossenkoppele,et al.  A threshold of 10% for myeloperoxidase by flow cytometry is valid to classify acute leukemia of ambiguous and myeloid origin , 2013, Cytometry. Part B, Clinical cytometry.

[339]  T. McConnell,et al.  Chromosome analysis of cryopreserved cells. , 1990, Cancer genetics and cytogenetics.

[340]  M. Borowitz,et al.  FLT3 mutations in myeloid sarcoma , 2004, British journal of haematology.

[341]  R. Arceci,et al.  The incidence and clinical significance of nucleophosmin mutations in childhood AML. , 2007, Blood.

[342]  R. Foà,et al.  A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol. , 2005, Blood.

[343]  Paola Fazi,et al.  Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. , 2005, The New England journal of medicine.

[344]  L. Shih,et al.  Clinical bleeding events and laboratory coagulation profiles in acute promyelocytic leukemia , 2012, European journal of haematology.

[345]  Guido Marcucci,et al.  Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. , 2010, Blood.

[346]  C. V. D. Schoot,et al.  Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia , 2011, Leukemia.

[347]  M. Caligiuri,et al.  FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. , 2010, Blood.

[348]  Howard Balshem,et al.  GRADE guidelines: 3. Rating the quality of evidence. , 2011, Journal of clinical epidemiology.

[349]  M. Fey,et al.  Risk Assessment in Patients with Acute Myeloid Leukemia and a Normal Karyotype , 2005, Clinical Cancer Research.

[350]  C. Pui,et al.  Central nervous system leukemia in children with acute nonlymphoblastic leukemia. , 1985, Blood.

[351]  P. Steinherz,et al.  Craniospinal irradiation for acute lymphoblastic leukemia with central nervous system disease at diagnosis: a report from the Children's Cancer Group. , 1996, International journal of radiation oncology, biology, physics.

[352]  Alessandra Spagnoli,et al.  Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia. , 2010, Blood.

[353]  F B Taylor,et al.  Towards Definition, Clinical and Laboratory Criteria, and a Scoring System for Disseminated Intravascular Coagulation , 2001, Thrombosis and Haemostasis.

[354]  K Wheatley,et al.  The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. , 1998, Blood.

[355]  M. Caligiuri,et al.  Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[356]  E. Dmitrovsky,et al.  Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor alpha clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[357]  S. Richards,et al.  Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21). , 2007, Blood.

[358]  E. Estey,et al.  Comparative analysis of flow cytometry and morphology for the detection of acute myeloid leukaemia cells in cerebrospinal fluid , 2016, British journal of haematology.

[359]  A. Seif Pediatric leukemia predisposition syndromes: clues to understanding leukemogenesis. , 2011, Cancer genetics.

[360]  M. Tallman,et al.  How I treat extramedullary acute myeloid leukemia. , 2011, Blood.

[361]  F. Rosner,et al.  Hodgkin's disease and acute leukemia. Report of eight cases and review of the literature. , 1975, The American journal of medicine.

[362]  I. M. Belyakov,et al.  Fixation and cryopreservation of whole blood and isolated mononuclear cells: Influence of different procedures on lymphocyte subset analysis by flow cytometry , 2005, Cytometry. Part B, Clinical cytometry.

[363]  C. J. Harrison,et al.  THE MANAGEMENT OF PATIENTS WITH LEUKAEMIA: THE ROLE OF CYTOGENETICS IN THIS MOLECULAR ERA , 2000, British journal of haematology.

[364]  F. Ortuño,et al.  Cryopreservation Modifies Flow‐Cytometric Analysis of Hemopoietic Cells , 1995, Vox sanguinis.

[365]  C. Scrideli,et al.  A simplified minimal residual disease polymerase chain reaction method at early treatment points can stratify children with acute lymphoblastic leukemia into good and poor outcome groups , 2009, Haematologica.

[366]  E. van den Berg,et al.  Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[367]  H. Shin,et al.  Fine‐needle aspiration biopsy of granulocytic sarcoma , 2000, Cancer.

[368]  C. Harrison,et al.  The detection and significance of chromosomal abnormalities in childhood acute lymphoblastic leukaemia. , 2001, Blood reviews.

[369]  W. Kamps,et al.  Prognostic significance of blasts in the cerebrospinal fluid without pleiocytosis or a traumatic lumbar puncture in children with acute lymphoblastic leukemia: experience of the Dutch Childhood Oncology Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[370]  Verena I Gaidzik,et al.  RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[371]  W. Chan,et al.  Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[372]  S. Fröhling,et al.  Diagnostic value of fluorescence in situ hybridization for the detection of genomic aberrations in older patients with acute myeloid leukemia. , 2005, Haematologica.

[373]  C. Bloomfield,et al.  Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure. , 1992, Seminars in oncology.

[374]  P. Vyas,et al.  Pathology and genetics: Tumours of haematopoietic and lymphoid tissues , 2001 .

[375]  M. König,et al.  Chromosome 14 copy number-dependent IGH gene rearrangement patterns in high hyperdiploid childhood B-cell precursor ALL: implications for leukemia biology and minimal residual disease analysis , 2009, Leukemia.

[376]  Anna L. Brown,et al.  Heritable GATA2 Mutations Associated with Familial Myelodysplastic Syndrome and Acute Myeloid Leukemia , 2011, Nature Genetics.

[377]  G. Ehninger,et al.  A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial. , 2010, Blood.

[378]  M. Tormo,et al.  Profile of polymorphisms of drug‐metabolising enzymes and the risk of therapy‐related leukaemia , 2007, British journal of haematology.

[379]  N. Rosenthal,et al.  Adequacy of powered vs manual bone marrow biopsy specimens: a retrospective review of sequential marrow aspirates and biopsies in 68 patients. , 2015, American journal of clinical pathology.

[380]  B. Leber,et al.  Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy. , 2008, Blood.

[381]  I. Wistuba,et al.  Optimizing the DNA yield for molecular analysis from cytologic preparations , 2016, Cancer cytopathology.

[382]  J. Byrne,et al.  A reliable method for total RNA extraction from frozen human bone marrow samples taken at diagnosis of acute leukaemia , 2002, Journal of clinical pathology.

[383]  P. Noris,et al.  Mutations in ANKRD26 are responsible for a frequent form of inherited thrombocytopenia: analysis of 78 patients from 21 families. , 2011, Blood.

[384]  J. Gribben,et al.  Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01. , 2007, Blood.

[385]  K. Wagner,et al.  Integrative prognostic risk score in acute myeloid leukemia with normal karyotype. , 2011, Blood.

[386]  S. Raimondi,et al.  Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. , 2010, Blood.

[387]  O. Nanassy,et al.  Capture of genomic DNA on glass microscope slides. , 2007, Analytical biochemistry.

[388]  K. Döhner,et al.  Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[389]  J. Choi,et al.  Detection of leukemic lymphoblasts in CSF is instrument-dependent. , 2012, American journal of clinical pathology.

[390]  E. Hoster,et al.  NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS). , 2006, Blood.

[391]  K. Hählen,et al.  Extramedullary infiltrates at diagnosis have no prognostic significance in children with acute myeloid leukaemia , 2001, Leukemia.

[392]  R. Foà,et al.  M4 acute myeloid leukemia: the role of eosinophilia and cytogenetics in treatment response and survival. The GIMEMA experience , 2008, Haematologica.

[393]  M. Andreeff,et al.  Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[394]  P. Vyas,et al.  Analysis of GATA1 mutations in Down syndrome transient myeloproliferative disorder and myeloid leukemia. , 2011, Blood.

[395]  Kevin K Dobbin,et al.  Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. , 2010, Blood.

[396]  U. Borate,et al.  Clinicopathological and molecular features of myeloid sarcoma as initial presentation of therapy-related myeloid neoplasms: a single institution experience , 2014, International Journal of Hematology.

[397]  B. Johansson,et al.  Proposals for standardized protocols for cytogenetic analyses of acute leukemias, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic myeloproliferative disorders, and myelodysplastic syndromes , 2007, Genes, chromosomes & cancer.

[398]  G. Ehninger,et al.  MLD according to the WHO classification in AML has no correlation with age and no independent prognostic relevance as analyzed in 1766 patients. , 2008, Blood.

[399]  E. Estey,et al.  FLT3 mutation and response to intensive chemotherapy in young adult and elderly patients with normal karyotype. , 2004, Leukemia research.

[400]  F. Appelbaum,et al.  Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience. , 2010, Blood.

[401]  Bas J. Wouters,et al.  Segmental uniparental disomy as a recurrent mechanism for homozygous CEBPA mutations in acute myeloid leukemia , 2007, Leukemia.

[402]  I. Elezović,et al.  International Society of Thrombosis and Hemostasis Scoring System for disseminated intravascular coagulation ≥6: a new predictor of hemorrhagic early death in acute promyelocytic leukemia , 2013, Medical Oncology.

[403]  K. Schmiegelow,et al.  Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia , 2010, Leukemia.

[404]  D. Arber,et al.  Extramedullary Myeloid Cell Tumors An Immunohistochemical and Morphologic Study of 28 Cases , 1993, The American journal of surgical pathology.

[405]  E. van den Berg,et al.  Cytogenetic analysis of cryopreserved bone marrow cells. , 2001, Cancer genetics and cytogenetics.

[406]  J. Anastasi,et al.  Acute Myeloid Leukemia With Recurrent Cytogenetic Abnormalities. , 2015, American journal of clinical pathology.

[407]  E. Thiel,et al.  Prognostic implications of mutations and expression of the Wilms tumor 1 (WT1) gene in adult acute T-lymphoblastic leukemia , 2010, Haematologica.

[408]  J. Wagner,et al.  Consistency of the initial cell acquisition procedure is critical to the standardization of CD34+ cell enumeration by flow cytometry: results of a pairwise analysis of umbilical cord blood units and cryopreserved aliquots , 2009, Transfusion.

[409]  S. Ha,et al.  The applicability of the WHO classification in paediatric AML. A NOPHO‐AML study , 2015, British journal of haematology.

[410]  S. Chang,et al.  Precursor B- or T-lymphoblastic lymphoma presenting with cutaneous involvement: a series of 13 cases including 7 cases of cutaneous T-lymphoblastic lymphoma. , 2014, Journal of the American Academy of Dermatology.

[411]  H. Dombret,et al.  Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association , 2011, Leukemia.

[412]  R. Aur,et al.  Extramedullary myeloid tumors in children: the limited value of local treatment. , 2000, Journal of pediatric hematology/oncology.

[413]  R. Foà,et al.  Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance. , 2008, Blood.

[414]  M. Schrappe,et al.  Diagnostic cerebrospinal fluid examination in children with acute lymphoblastic leukemia: significance of low leukocyte counts with blasts or traumatic lumbar puncture. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[415]  R. Schlenk,et al.  Prognosis of acute myeloid leukemia patients up to 60 years of age exhibiting trisomy 8 within a non-complex karyotype: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup. , 2007, Haematologica.

[416]  Pu Zhang,et al.  Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-α (C/EBPα), in acute myeloid leukemia , 2001, Nature Genetics.

[417]  Y. Ning,et al.  Myeloid sarcomas: a histologic, immunohistochemical, and cytogenetic study , 2007, Diagnostic pathology.

[418]  H. Kantarjian,et al.  Usefulness of CD11a and CD18 in flow cytometric immunophenotypic analysis for diagnosis of acute promyelocytic leukemia. , 2012, American journal of clinical pathology.

[419]  A Orfao,et al.  2006 Bethesda International Consensus recommendations on the flow cytometric immunophenotypic analysis of hematolymphoid neoplasia: Medical indications , 2007, Cytometry. Part B, Clinical cytometry.

[420]  T. A. Lister,et al.  Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[421]  K. Wagner,et al.  ID1 expression associates with other molecular markers and is not an independent prognostic factor in cytogenetically normal acute myeloid leukaemia , 2012, British journal of haematology.

[422]  M. Caligiuri,et al.  Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[423]  C. Nerlov C/EBPα mutations in acute myeloid leukaemias , 2004, Nature Reviews Cancer.

[424]  D. Neuberg,et al.  Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[425]  F. Mandelli,et al.  Treatment of acute myelogenous leukemia in children: results of the Italian Cooperative Study AIEOP/LAM 8204. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[426]  Guido Marcucci,et al.  RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[427]  C. Bloomfield,et al.  Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[428]  Medicare, Medicaid, and CLIA programs; laboratory requirements relating to quality systems and certain personnel qualifications. Final rule. , 2003, Federal register.

[429]  R. Pieters,et al.  Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia. , 2009, Blood.

[430]  N. Socci,et al.  Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. , 2012, The New England journal of medicine.

[431]  D. Gemmati,et al.  Gene polymorphisms in folate metabolizing enzymes in adult acute lymphoblastic leukemia: effects on methotrexate-related toxicity and survival , 2009, Haematologica.

[432]  Marcos González,et al.  High FOXO3a expression is associated with a poorer prognosis in AML with normal cytogenetics. , 2009, Leukemia research.

[433]  K. Döhner,et al.  Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.